

Repression of YAP by NCTD disrupts NSCLC progression

Jiwei Guo^{1,*}, Yan Wu^{1,*}, Lijuan Yang¹, Jing Du¹, Kaikai Gong¹, Weiwei Chen¹, Juanjuan Dai¹, XueLin Li¹ and Sichuan Xi¹

¹Cancer Research Institute, Binzhou Medical University Hospital, Binzhou 256603, P.R. China

*These authors contributed equally to this work

Published:

Copyright: Guo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: While organizing the results of Figure 6, the GAPDH band in Figure 3D was inadvertently used for the band of GAPDH in Figure 6C, owing to the same treatment in the A549 cells. The correct Figure 6C is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:2307–2319. <https://doi.org/10.18632/oncotarget.13668>




Figure 6: NCTD interferes the Yap-mediated NSCLC cell invasiveness and EMT. (A) Scratch assay showing treatment of NCTD at 15 μM for 12–24 hours dramatically decreased Yap-induced enhancement in A549 cell migration. (B) Matrigel invasion assay identified that treatment of NCTD at 15 μM for 72 hours dramatically decreased cell invasive growth and overexpressing YAP partially blocked NCTD-induced inhibition in cell invasive growth. (C, D) NCTD dose-dependently increased E-cadherin and increased fibronectin and vimentin in mRNA(C) and protein (D) level in A549 cells for 72 hours. *** $P < 0.0001$ by Student's *t*-test. ** $P < 0.001$ *** $P < 0.0001$ by Student's *t*-test.